Using chemotherapy-sensitive/resistant mouse models, we demonstrated that treatment with MSV-EphA2 siRNA significantly decreased the tumor burden usually characteristic of HeyA8-MDR-induced tumor-bearing mice12. The gene discussed is EPHA2; the disease is neoplasm.